<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299960</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO-CEC</org_study_id>
    <nct_id>NCT02299960</nct_id>
  </id_info>
  <brief_title>Measurement of Endothelial Function and Cardiac Output: New Methods</brief_title>
  <official_title>Pilot Study: Analysis of Endothelial Function Through Circulating Endothelial Cells and Puls-amplitude-tonometry and of Non-invasive Measurement of Cardiac Output on Exertion in Patients With Heart Failure, Pulmonary Hypertension, Arterial Hypertension and Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Twist GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to analyse test-retest-reliability of functional&#xD;
      quantification of endothelial dysfunction through puls-amplitude-tonometry in patients with&#xD;
      heart failure with preserved/reduced ejection fraction, pulmonary hypertension, arterial&#xD;
      hypertension and diabetic nephropathy. In the same group, test-retest-reliability of&#xD;
      circulating endothelial cells as well as test-retest reliability of non invasive cardiac&#xD;
      output Monitoring will be observed and analysed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test-retest-reliability EndoPAT</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test-retest-reliability circulating endothelial cells</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test-retest-reliability NICOM</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation: Cardiac Output on exertion and cardiopulmonary exercise test and 6 Minute Walking test</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation: circulating endothelial cells and EndoPAT and endothelial function</measure>
    <time_frame>2 weeks</time_frame>
    <description>will include the molecular diagnostic of circulating endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of biomarkers of myocardiac remodelling and of cardiorenal syndrome</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation cardiac Output on exertion and echocardiography in HFpEF</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical feasibility of circulating endothelial cells and EndoPAT</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">101</enrollment>
  <condition>Heart Failure</condition>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Hypertension</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <description>patients with heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <description>patients with heart failure with reduced ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AH</arm_group_label>
    <description>patients with hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nephropathy</arm_group_label>
    <description>patients with diabetic nephropathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endo-PAT</intervention_name>
    <description>Analysis of endothelial function through pulse-amplitude-tonometry</description>
    <arm_group_label>AH</arm_group_label>
    <arm_group_label>HFpEF</arm_group_label>
    <arm_group_label>HFrEF</arm_group_label>
    <arm_group_label>Nephropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NICOM</intervention_name>
    <description>Non-invasive measurement of cardiac output</description>
    <arm_group_label>AH</arm_group_label>
    <arm_group_label>HFpEF</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, 51,4ml per Patient&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from the conditions stated above&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically stable for the last 4 weeks (not for HFrEF: 7 days)&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
        HFpEF:&#xD;
&#xD;
          -  Baseline-Echocardiography:&#xD;
&#xD;
          -  hospitalization &lt;= 12 months with diagnosis heart failure and E/E' &gt; 8 or E' &lt; 8 cm/s&#xD;
             or&#xD;
&#xD;
          -  BNP &gt;= 100pg/ml or NT-proBNP &gt;= 300pg/ml in the last 6 months or&#xD;
&#xD;
          -  LAVI &gt; 28 ml/m² and E/E' &gt; 8 or E' &lt; 8cm/s or PAPsys &gt; 40mmHg and E/E' &gt; 8 or E' &lt; 8&#xD;
             cm/s&#xD;
&#xD;
          -  Possibility to take part in cardiac stress test&#xD;
&#xD;
          -  Heart failure NYHA I-III&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
          -  Max. O2-uptake on exertion &lt; 20ml/kgBW/min&#xD;
&#xD;
        HFrEF&#xD;
&#xD;
          -  HFrEF due to ischemic or non-ischemic reasons&#xD;
&#xD;
          -  NYHA I-III&#xD;
&#xD;
          -  Individually optimized and stable pharmacological therapy (including beta-blocker,&#xD;
             ACE-Inhibitor, AT1-antagonist, aldosterone-antagonist)&#xD;
&#xD;
          -  EF &lt;=45%, Simpson Biplan PH&#xD;
&#xD;
          -  NICE-Classification 2013 I/II&#xD;
&#xD;
          -  PAH &gt;= 25 mmHg&#xD;
&#xD;
          -  Precapillary PAH: Wedge-pressure &lt;= 15 mmHg, CO normal or low&#xD;
&#xD;
          -  Postcapillary PAH: Wedge-pressure &gt;= 15 mmHg, CO normal or low&#xD;
&#xD;
        Diabetic nephropathy:&#xD;
&#xD;
          -  Diabetes mellitus Type 2 with oral or Insulin therapy and one or more of the&#xD;
             following:&#xD;
&#xD;
          -  Diabetic nephropathy has been diagnosed before (anamnesis)&#xD;
&#xD;
          -  Macroalbuminuria: Urine Albumine/Creatinine-ratio &gt; 300mg/g Creatinine (&gt;34mg/mmol) in&#xD;
             2 out of 3 tests of Urine in the morning and GFR &lt;90ml/min/1.73m² (CKD-EPI)&#xD;
&#xD;
          -  Microalbuminuria: 30-300mg/g Creatinine (&gt;=3.4 mg/mmol but &lt;34mg/mmol) tested as above&#xD;
             and GFR &lt; 90 ml/min/1.73m² and diabetic retinopathy&#xD;
&#xD;
        AH:&#xD;
&#xD;
          -  Hypertension diagnosed at least 6 months except structural heart disease: EF &gt; 55% and&#xD;
             no sign of HFpEF&#xD;
&#xD;
          -  No symptoms of coronary heart disease&#xD;
&#xD;
          -  Possibility to take part in cardiac stress test&#xD;
&#xD;
          -  Stable pharmacologic therapy of Hypertension for at least 4 weeks&#xD;
&#xD;
          -  Systolic blood pressure &lt;140 mmHG during Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient incapable of contracting&#xD;
&#xD;
          -  Angina pectoris &gt; CCS II&#xD;
&#xD;
          -  Coronary Intervention in the last 4 weeks or scheduled Intervention/Bypass&#xD;
&#xD;
          -  Myocardial infarction in the last 3 months&#xD;
&#xD;
          -  Stroke in the last 3 months&#xD;
&#xD;
          -  Valvular heart disease &gt; II°&#xD;
&#xD;
          -  Cardiomyopathy due to Infiltrate/hypertrophic obstruction (e.g. HOCM, Amyloidosis)&#xD;
&#xD;
          -  Congenital complex heart disease&#xD;
&#xD;
          -  Active myocarditis&#xD;
&#xD;
          -  Significant lung disease&#xD;
&#xD;
          -  Significant Cardiac dysrhythmia&#xD;
&#xD;
          -  Scheduled changes in medication during time of study&#xD;
&#xD;
          -  (Scheduled) heart transplant&#xD;
&#xD;
          -  Cardiac resynchronisation therapy over the last three months&#xD;
&#xD;
          -  ICD/Pacemaker-implant in the last 4 weeks&#xD;
&#xD;
          -  Uncontrolled Hyper/Hypotension (&gt;180mmHg, &lt;95mmHg)&#xD;
&#xD;
          -  Patient taking part in Rehabilitation program&#xD;
&#xD;
          -  Diagnosed Malignant disease or disease with life expectancy &lt; 1 year&#xD;
&#xD;
          -  Anemia with Hb&lt;10mg/dl&#xD;
&#xD;
          -  Untreated significant thyroid disease&#xD;
&#xD;
        HFpEF, Hypertension and PH:&#xD;
&#xD;
          -  Patient incapable of cardiac stress test (e.g. because of orthopedic Problems)&#xD;
&#xD;
          -  Significant changes in cardiovascular Status over the two weeks of study&#xD;
&#xD;
          -  Instable cardiopulmonary Status over the last four weeks&#xD;
&#xD;
        HFrEF:&#xD;
&#xD;
          -  I.v. Treatment with inotropic drug or diuretic in the last 7 days before Screening&#xD;
&#xD;
          -  Myocardial infarction in the last 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Dirk Duengen, PD Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Charite Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Sebastian Beckmann</investigator_full_name>
    <investigator_title>Doctoral candidate</investigator_title>
  </responsible_party>
  <keyword>EndoPAT</keyword>
  <keyword>NICOM</keyword>
  <keyword>circulating endothelial cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

